New Tbit™ platform, a rapid, point-of-care diagnostic device for concussion, has been selected as a finalist in Startup Showdown Contest
April 2, 2015
Boston, MA – (BUSINESS WIRE) – BioDirection, Inc. announced today that its new Tbit™ platform, a rapid, point-of-care device for the objective identification of mild traumatic brain injury (concussion), has been selected by the Medical Device and Diagnostic Industry Journal (MDDI) as a finalist in its first ever Startup Showdown Competition. BioDirection's Tbit™ platform utilizes patented bio-nanowire technology that can detect and measure minute levels of "biomarker" proteins released from the brain after a concussion. The technology provides first-in-class critical and objective information to aid in the diagnosis of a concussion from a single drop of blood in less than 90 seconds.
"We are honored to be recognized as a finalist in this competition sponsored by MDDI, one of the preeminent trade journals in the medical device and diagnostic industry. This acknowledgment underscores the urgent need for an objective test for concussions and validates BioDirection's pioneering work to fulfill that need," said Eric Goorno, Chief Executive Officer, BioDirection. "Traumatic brain injury has become a widespread concern, and the Tbit™ platform will provide front-line point-of-care personnel new objective information to aid in the immediate diagnosis of a concussion."
Medical Device and Diagnostic Industry (MDDI) is an online and print resource. Its mission is to help medtech industry professionals develop, design, and manufacture products that comply with complex and demanding regulations and evolving market requirements. Some of the best and brightest experts in medtech contribute to MDDI, and many of their articles have become standards of reference for the medical device industry.
BioDirection, Inc. is a privately-held medical device company focused on the design, development and commercialization of easy-to-use, rapid, point-of-care devices for the objective identification of mild traumatic brain injury (concussion). BioDirection's platform technology utilizes patented bio-nanowire technology, which is poised to become the standard of care for the objective diagnosis, prognosis and status of acquired brain injuries. To learn more about BioDirection visit: http://www.biodirection.com.
Eric Goorno, Chief Executive Officer
Tel: (508) 308-8592
BioDirection is always searching for new opportunities. Contact us today with any questions or inquiries.